3 Healthcare Stock Stories For Monday Investment Wellness

Celgene Corporation (NASDAQ: CELG): Closing price $121.22

Celgene Corporation’s subsidiary Celgene International Sàrl, announced Monday that statistical significance was attained for the primary endpoint of ACR 20 at week 16 for patients receiving apremilast 20 mg and 30 mg BID monotherapy in PALACE 4. This is the fourth randomized, placebo-controlled study evaluating the firm’s novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) in patients sufferingwith psoriatic arthritis. This marks the first Celgene-sponsored trial evaluating patients who had not previously received an oral disease-modifying antirheumatic drug .

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CELG

 CytRx Corporation (NASDAQ:CYTR): Closing price $2.64

The biopharmaceutical research and development firm announced that the independent Data Safety Monitoring Committee overseeing its international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma, has recommended continuing the clinical trial through completion. This Phase 2b trial permits a head-to-head clinical comparison of the commonly used chemotherapeutic agent doxorubicin with aldoxorubicin, CytRxs tumor-targeting doxorubicin conjugate. Doxorubicin is dose-limited at a level under its maximum anti-tumor capabilities due to toxicity, among which includes cardiotoxicity. Data from the Phase 2b trial is expected in the second half of the year.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CYTR

Regeneron Pharmaceuticals (NASDAQ:REGN): Closing price $262.75

Analyst Biren Arnin at Jefferies in a report published Monday, reiterated a Hold on the shares and raised the price target from $179 to $247. In the report, Arnin commented that “REGN reported a top-line beat driven by U.S. Eylea sales leading to slightly raised guidance. Given the recent strength in REGN shares attributed to Avastin cmpding issues, there appeared to be very little shift away from Avastin. We have, however, raised our PT to $247 largely due to increased traction in ex-U.S. Eylea sales and the value for PIII alirocumab for hypercholesterolemia.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

REGN

Don’t Miss: Can Johnson & Johnson Deal With This Publicity Fiasco?